Changes In Serum Tarc Predict Pet Response Among Pediatric Patients With Relapsed Or Refractory Hodgkin Lymphoma Treated With Brentuximab Vedotin And Gemcitabine: A Report From The Children'S Oncology Group

Patients with primary refractory Hodgkin lymphoma (HL) or who relapse less than one year after completion of initial therapy will frequently respond to second line therapy. A majority of those who have a complete response (CR) to salvage therapy, and are then consolidated with high-dose chemotherapy and autologous stem cell rescue will experience prolonged relapse-free survival. It is therefore critical to identify those patients who are unlikely to respond to a given salvage regimen, so they can be given alternate treatment.